IMPDH Antibody (F-6): sc-166551

IMPDH Antibody (F-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects IMPDH protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IMPDH Antibody (F-6) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Inosine-5′-monophosphate dehydrogenase 1 (IMPDH1), a member of the guanosine monophosphate reductase family, plays a crucial role in regulating cell growth by catalyzing the rate-limiting step in the de novo synthesis of guanine nucleotides. IMPDH1 is predominantly expressed in photoreceptors, where IMPDH1 is essential for cyclic nucleoside metabolism, highlighting IMPDH1′s importance in maintaining cellular function and integrity. Notably, while IMPDH1 is the primary isoform found in normal leukocytes, IMPDH2 is more prevalent in various tumors, indicating a potential shift in metabolic pathways during oncogenesis. Mutations in IMPDH1 have been linked to autosomal dominant retinitis pigmentosa type 10 (RP10) and the development of malignant tumors, with studies suggesting that protein misfolding and aggregation, rather than reduced enzymatic activity, contribute to the severe phenotypes observed in these conditions. Consequently, IMPDH1 presents a promising therapeutic target, particularly through strategies that involve the simultaneous suppression of IMPDH1 transcripts alongside the supplementation of guanosine triphosphate in retinal tissues.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IMPDH Antibody (F-6) References:

1. [Effect of immune lymphocytes on the postvaccinal cytoserological reaction in foot-and-mouth disease].  |  Gorskiĭ, BV. 1977. Veterinariia. 43-4. PMID: 0878288
2. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa.  |  Bowne, SJ., et al. 2002. Hum Mol Genet. 11: 559-68. PMID: 11875050
3. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa.  |  Aherne, A., et al. 2004. Hum Mol Genet. 13: 641-50. PMID: 14981049
4. Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target.  |  Pankiewicz, KW., et al. 2004. Curr Med Chem. 11: 887-900. PMID: 15083807
5. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.  |  Wright, DG., et al. 2004. Leuk Res. 28: 1137-43. PMID: 15380336
6. Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery.  |  Shu, Q. and Nair, V. 2008. Med Res Rev. 28: 219-32. PMID: 17480004
7. The dynamic determinants of reaction specificity in the IMPDH/GMPR family of (β/α)(8) barrel enzymes.  |  Hedstrom, L. 2012. Crit Rev Biochem Mol Biol. 47: 250-63. PMID: 22332716
8. Synthesis of the inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors.  |  Cholewiński, G., et al. 2015. J Enzyme Inhib Med Chem. 30: 550-63. PMID: 25198892
9. Inosine 5'-Monophosphate Dehydrogenase (IMPDH) as a Potential Target for the Development of a New Generation of Antiprotozoan Agents.  |  Fotie, J. 2018. Mini Rev Med Chem. 18: 656-671. PMID: 27334467
10. Nuclear IMPDH Filaments in Human Gliomas.  |  Ahangari, N., et al. 2021. J Neuropathol Exp Neurol. 80: 944-954. PMID: 34498062
11. The roles of HDAC with IMPDH and mTOR with JAK as future targets in the treatment of rheumatoid arthritis with combination therapy.  |  Mane, RR. and Kale, PP. 2023. J Complement Integr Med. 20: 689-706. PMID: 36409592
12. IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.  |  Liu, X., et al. 2023. EMBO Mol Med. 15: e15631. PMID: 36453131

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IMPDH Antibody (F-6) has 7 citations in a variety of scientific publications.

Primary antibodies like Anti-IMPDH Antibody (F-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IMPDH Antibody (F-6) Specifications

Alternate Product Name: IMPDH

Product Clone Name: F-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 392-409

Epitope Target: IMPDH

Epitope Species: human

Product Reactivity/Detection: IMPDH1 and IMPDH2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 7 citations in various scientific publications

Available Conjugates/Forms for IMPDH Antibody (F-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin